NCT04191616 2025-09-04
SELECT
Amgen
Phase 2 Completed
Clinical Trials
16 trialsNCT06163040 2025-07-31
A Study to Evaluate the Safety of EmplicitiĀ® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan
Bristol-Myers Squibb
Completed
NCT03288974 2025-04-15
Pomalyst PMS
Celgene
Completed
NCT02616640 2024-09-19
A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT02206425 2023-10-31
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Phase 1/2 Completed
NCT03439280 2023-02-24
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Takeda
Phase 1/2 Completed
NCT01712789 2022-01-10
STRATUS
Celgene
Phase 3 Completed
NCT01177735 2021-04-22
Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma
University of Arkansas
Phase 2 Completed
NCT01497093 2020-04-07
Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT02189343 2019-11-21
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT01324947 2019-11-19
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma
Celgene
Phase 3 Completed
NCT02176213 2019-06-18
Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT02103335 2017-11-22
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT02046915 2017-10-30
PERSPECTIVE
University Hospital Tuebingen
Phase 2 Completed
NCT01432600 2017-05-23
Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
NCT02011113 2016-11-01
Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma
Celgene Corporation
Phase 2 Completed